Seek Returns

AZN vs. BIO.B: AstraZeneca vs. Bio-Rad Laboratories Stock Comparison

How do AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while BIO.B is classified in Life Sciences Tools & Services.

Bio-Rad Laboratories (BIO.B) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
Profile ItemAZNBIO.B
NameAstraZeneca PLC American Depositary SharesBio-Rad Laboratories, Inc. Class B Common Stock
Country/RegionUnited KingdomUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsLife Sciences Tools & Services
GICS Sub-IndustryPharmaceuticalsLife Sciences Tools & Services
Market Capitalization289.14 billion USD10.49 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateMay 12, 1993September 21, 1999
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

AZN
BIO.B
GSPC
Loading price history…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Total Return (1Y)12.64%27.69%
Total Return (3Y, Annualized)15.75%9.13%
Total Return (5Y, Annualized)10.63%-12.33%

Risk Profile

Drawdown History

AZN
BIO.B
GSPC
Loading price history…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

AstraZeneca (AZN) trades around 3.14M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Volatility (1Y, Annualized)28.21%30.96%
Beta (5Y)0.221.00
Max Drawdown (5Y)-27.87%-70.74%
Avg. Volume (3M)3.14M11

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AZN and BIO.B are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Sharpe Ratio (1Y)0.300.74
Sortino Ratio (1Y)0.441.10

Profitability

ROE (TTM)

Both AstraZeneca (AZN) at 22.57% and Bio-Rad Laboratories (BIO.B) at 14.27% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max
109.18%
AZN
22.57%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and AstraZeneca (AZN) at 17.68% also retains a top-quartile share.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max
18.05%
AZN
17.68%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AstraZeneca (AZN) at 29.57% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max
83.12%
AZN
29.57%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
ROE (TTM)22.57%14.27%
ROA (TTM)8.59%1.50%
Net Margin (TTM)17.68%39.45%
Operating Margin (TTM)29.57%9.46%
Gross Margin (TTM)81.78%52.19%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Bio-Rad Laboratories (BIO.B) at 0.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: AstraZeneca (AZN) reports EPS growth of 45.33%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Revenue Growth (YoY)8.63%0.65%
Revenue Growth (3Y CAGR)9.82%-2.68%
EPS Growth (YoY)45.33%--
EPS Growth (3Y CAGR)45.80%--

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while AstraZeneca (AZN) at 1.01 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AZN.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AZN
1.01
Min
0.10

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max
1.42
AZN
0.66
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Current Ratio (MRQ)1.013.18
Debt / Equity (MRQ)0.660.18
Net Debt / EBITDA1.23-0.73

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO.B) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN
1.73%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Bio-Rad Laboratories (BIO.B) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN
45.38%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
Dividend Yield (TTM)1.73%0.00%
Dividend Payout Ratio (TTM)45.38%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while AstraZeneca (AZN) at 26.37 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max
85.34
Q3
43.46
Median
26.69
AZN
26.37
Q1
13.30
Min
0.07

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AstraZeneca (AZN) at 4.63 and Bio-Rad Laboratories (BIO.B) at 4.05 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max
58.18
Q3
25.77
Median
7.30
AZN
4.63
Q1
3.01
Min
0.01

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while AstraZeneca (AZN) at 5.59 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max
13.53
Q3
6.54
AZN
5.59
Median
3.25
Q1
1.69
Min
-5.59

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59
Loading chart…
AstraZeneca (AZN) vs. Bio-Rad Laboratories (BIO.B): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Bio-Rad Laboratories (BIO.B)
MetricAZNBIO.B
P/E Ratio (TTM)26.3710.36
P/S Ratio (TTM)4.634.05
P/B Ratio (MRQ)5.591.38
Free Cash Flow Yield (TTM)1.95%2.59%